NRx Pharmaceuticals Completes Memorandum Of Understanding And Collaborations WIth Distribution Partners For HTX-100
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals, Inc. (NRXP) and its subsidiary HOPE Therapeutics have completed a Memorandum of Understanding with Conversio Health and established a partnership with Nephron Pharmaceuticals for the distribution of IV Ketamine. This collaboration aims to provide a consistent supply of high-quality, FDA- and DEA-compliant IV ketamine to patients and clinics nationwide. The company is preparing for the initial sale of ketamine by the end of March 2024 and plans to file a New Drug Application (NDA) for HTX-100, with a potential launch in early 2025.
March 11, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRx Pharmaceuticals announces partnerships for IV Ketamine distribution and plans for HTX-100 launch in early 2025.
The completion of a Memorandum of Understanding with Conversio Health and a partnership with Nephron Pharmaceuticals for the distribution of IV Ketamine positions NRx Pharmaceuticals (NRXP) for potential growth. The planned filing of a New Drug Application for HTX-100 and its potential launch in early 2025 could significantly impact the company's product portfolio and market position. These developments are likely to be viewed positively by investors, potentially leading to a short-term increase in NRXP's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100